Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

STVN vs WST vs GTLS vs BDX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
STVN
Stevanato Group S.p.A.

Medical - Instruments & Supplies

HealthcareNYSE • IT
Market Cap$4.98B
5Y Perf.-9.7%
WST
West Pharmaceutical Services, Inc.

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$23.49B
5Y Perf.-20.8%
GTLS
Chart Industries, Inc.

Industrial - Machinery

IndustrialsNYSE • US
Market Cap$9.93B
5Y Perf.+33.4%
BDX
Becton, Dickinson and Company

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$54.14B
5Y Perf.-3.0%

STVN vs WST vs GTLS vs BDX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
STVN logoSTVN
WST logoWST
GTLS logoGTLS
BDX logoBDX
IndustryMedical - Instruments & SuppliesMedical - Instruments & SuppliesIndustrial - MachineryMedical - Instruments & Supplies
Market Cap$4.98B$23.49B$9.93B$54.14B
Revenue (TTM)$1.18B$3.22B$4.26B$21.36B
Net Income (TTM)$139M$543M$40M$1.14B
Gross Margin29.0%36.2%32.6%46.5%
Operating Margin16.5%20.7%8.5%10.6%
Forward P/E29.5x37.8x16.4x11.9x
Total Debt$471M$417M$3.74B$19.18B
Cash & Equiv.$131M$791M$366M$851M

STVN vs WST vs GTLS vs BDXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

STVN
WST
GTLS
BDX
StockJul 21May 26Return
Stevanato Group S.p… (STVN)10090.3-9.7%
West Pharmaceutical… (WST)10079.2-20.8%
Chart Industries, I… (GTLS)100133.4+33.4%
Becton, Dickinson a… (BDX)10097.0-3.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: STVN vs WST vs GTLS vs BDX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: WST and BDX are tied at the top with 3 categories each — the right choice depends on your priorities. Becton, Dickinson and Company is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. GTLS also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
STVN
Stevanato Group S.p.A.
The Secondary Option

STVN lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
WST
West Pharmaceutical Services, Inc.
The Defensive Pick

WST carries the broadest edge in this set and is the clearest fit for sleep-well-at-night.

  • Lower volatility, beta 0.91, Low D/E 13.1%, current ratio 3.02x
  • 16.9% margin vs GTLS's 0.9%
  • +52.2% vs STVN's -18.6%
  • 13.2% ROA vs GTLS's 0.4%, ROIC 17.5% vs 7.4%
Best for: sleep-well-at-night
GTLS
Chart Industries, Inc.
The Long-Run Compounder

GTLS is the clearest fit if your priority is long-term compounding and defensive.

  • 7.7% 10Y total return vs WST's 367.1%
  • Beta 0.49, yield 0.3%, current ratio 1.36x
  • Beta 0.49 vs STVN's 1.47
Best for: long-term compounding and defensive
BDX
Becton, Dickinson and Company
The Income Pick

BDX is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.

  • Dividend streak 1 yrs, beta 0.62, yield 2.8%
  • Rev growth 8.2%, EPS growth -0.5%, 3Y rev CAGR 5.0%
  • PEG 0.72 vs WST's 4.57
  • 8.2% revenue growth vs GTLS's 2.5%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthBDX logoBDX8.2% revenue growth vs GTLS's 2.5%
ValueBDX logoBDXLower P/E (11.9x vs 16.4x)
Quality / MarginsWST logoWST16.9% margin vs GTLS's 0.9%
Stability / SafetyGTLS logoGTLSBeta 0.49 vs STVN's 1.47
DividendsBDX logoBDX2.8% yield, 1-year raise streak, vs WST's 0.3%
Momentum (1Y)WST logoWST+52.2% vs STVN's -18.6%
Efficiency (ROA)WST logoWST13.2% ROA vs GTLS's 0.4%, ROIC 17.5% vs 7.4%

STVN vs WST vs GTLS vs BDX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

STVNStevanato Group S.p.A.

Segment breakdown not available.

WSTWest Pharmaceutical Services, Inc.
FY 2025
Proprietary Products
81.1%$2.5B
Contract Manufactured Products
18.9%$582M
GTLSChart Industries, Inc.
FY 2025
Repair, Service And Leasing Segment
30.6%$1.3B
Heat Transfer Systems Segment
29.0%$1.2B
Specialty Products Segment
25.8%$1.1B
Cryo Tank Solutions Segment
14.6%$624M
BDXBecton, Dickinson and Company
FY 2025
Medical
52.5%$11.5B
Interventional
23.9%$5.2B
Life Sciences
23.7%$5.2B

STVN vs WST vs GTLS vs BDX — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLWSTLAGGINGSTVN

Income & Cash Flow (Last 12 Months)

WST leads this category, winning 4 of 6 comparable metrics.

BDX is the larger business by revenue, generating $21.4B annually — 18.1x STVN's $1.2B. WST is the more profitable business, keeping 16.9% of every revenue dollar as net income compared to GTLS's 0.9%. On growth, WST holds the edge at +21.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSTVN logoSTVNStevanato Group S…WST logoWSTWest Pharmaceutic…GTLS logoGTLSChart Industries,…BDX logoBDXBecton, Dickinson…
RevenueTrailing 12 months$1.2B$3.2B$4.3B$21.4B
EBITDAEarnings before interest/tax$283M$794M$644M$4.2B
Net IncomeAfter-tax profit$139M$543M$40M$1.1B
Free Cash FlowCash after capex$16M$458M$203M$3.1B
Gross MarginGross profit ÷ Revenue+29.0%+36.2%+32.6%+46.5%
Operating MarginEBIT ÷ Revenue+16.5%+20.7%+8.5%+10.6%
Net MarginNet income ÷ Revenue+11.8%+16.9%+0.9%+5.3%
FCF MarginFCF ÷ Revenue+1.4%+14.2%+4.8%+14.7%
Rev. Growth (YoY)Latest quarter vs prior year+3.8%+21.0%-2.5%-10.6%
EPS Growth (YoY)Latest quarter vs prior year-5.6%+56.1%-36.1%-2.0%
WST leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

BDX leads this category, winning 5 of 7 comparable metrics.

At 25.6x trailing earnings, BDX trades at a 96% valuation discount to GTLS's 628.6x P/E. Adjusting for growth (PEG ratio), BDX offers better value at 1.55x vs WST's 5.79x — a lower PEG means you pay less per unit of expected earnings growth.

MetricSTVN logoSTVNStevanato Group S…WST logoWSTWest Pharmaceutic…GTLS logoGTLSChart Industries,…BDX logoBDXBecton, Dickinson…
Market CapShares × price$5.0B$23.5B$9.9B$54.1B
Enterprise ValueMkt cap + debt − cash$5.4B$23.1B$13.3B$72.5B
Trailing P/EPrice ÷ TTM EPS31.70x47.93x628.58x25.63x
Forward P/EPrice ÷ next-FY EPS est.29.46x37.80x16.40x11.90x
PEG RatioP/E ÷ EPS growth rate2.68x5.79x1.55x
EV / EBITDAEnterprise value multiple17.08x31.17x14.33x14.38x
Price / SalesMarket cap ÷ Revenue3.72x7.64x2.33x2.48x
Price / BookPrice ÷ Book value/share2.85x7.46x2.79x1.69x
Price / FCFMarket cap ÷ FCF197.82x50.10x48.96x20.28x
BDX leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

WST leads this category, winning 8 of 9 comparable metrics.

WST delivers a 17.9% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $1 for GTLS. WST carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to GTLS's 1.11x. On the Piotroski fundamental quality scale (0–9), BDX scores 7/9 vs GTLS's 5/9, reflecting strong financial health.

MetricSTVN logoSTVNStevanato Group S…WST logoWSTWest Pharmaceutic…GTLS logoGTLSChart Industries,…BDX logoBDXBecton, Dickinson…
ROE (TTM)Return on equity+9.7%+17.9%+1.2%+4.5%
ROA (TTM)Return on assets+5.8%+13.2%+0.4%+2.1%
ROICReturn on invested capital+7.7%+17.5%+7.4%+4.3%
ROCEReturn on capital employed+9.5%+18.4%+8.6%+5.4%
Piotroski ScoreFundamental quality 0–95657
Debt / EquityFinancial leverage0.32x0.13x1.11x0.76x
Net DebtTotal debt minus cash$340M-$375M$3.4B$18.3B
Cash & Equiv.Liquid assets$131M$791M$366M$851M
Total DebtShort + long-term debt$471M$417M$3.7B$19.2B
Interest CoverageEBIT ÷ Interest expense20.54x3338.00x1.08x4.09x
WST leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

GTLS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in GTLS five years ago would be worth $14,063 today (with dividends reinvested), compared to $9,384 for STVN. Over the past 12 months, WST leads with a +52.2% total return vs STVN's -18.6%. The 3-year compound annual growth rate (CAGR) favors GTLS at 17.6% vs STVN's -13.5% — a key indicator of consistent wealth creation.

MetricSTVN logoSTVNStevanato Group S…WST logoWSTWest Pharmaceutic…GTLS logoGTLSChart Industries,…BDX logoBDXBecton, Dickinson…
YTD ReturnYear-to-date-11.4%+18.1%+0.6%-1.8%
1-Year ReturnPast 12 months-18.6%+52.2%+31.8%+47.3%
3-Year ReturnCumulative with dividends-35.2%-10.5%+62.7%+2.6%
5-Year ReturnCumulative with dividends-6.2%-1.2%+40.6%+10.9%
10-Year ReturnCumulative with dividends-6.2%+367.1%+772.7%+76.4%
CAGR (3Y)Annualised 3-year return-13.5%-3.6%+17.6%+0.8%
GTLS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

GTLS leads this category, winning 2 of 2 comparable metrics.

GTLS is the less volatile stock with a 0.49 beta — it tends to amplify market swings less than STVN's 1.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GTLS currently trades 99.5% from its 52-week high vs STVN's 65.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSTVN logoSTVNStevanato Group S…WST logoWSTWest Pharmaceutic…GTLS logoGTLSChart Industries,…BDX logoBDXBecton, Dickinson…
Beta (5Y)Sensitivity to S&P 5001.47x0.91x0.49x0.62x
52-Week HighHighest price in past year$28.00$328.44$208.51$205.52
52-Week LowLowest price in past year$12.89$202.79$140.50$100.31
% of 52W HighCurrent price vs 52-week peak+65.1%+99.2%+99.5%+72.7%
RSI (14)Momentum oscillator 0–10067.776.643.850.9
Avg Volume (50D)Average daily shares traded586K846K1.6M2.5M
GTLS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — WST and BDX each lead in 1 of 2 comparable metrics.

Analyst consensus: STVN as "Buy", WST as "Buy", GTLS as "Buy", BDX as "Hold". Consensus price targets imply 34.4% upside for STVN (target: $25) vs -6.6% for GTLS (target: $194). For income investors, BDX offers the higher dividend yield at 2.79% vs WST's 0.26%.

MetricSTVN logoSTVNStevanato Group S…WST logoWSTWest Pharmaceutic…GTLS logoGTLSChart Industries,…BDX logoBDXBecton, Dickinson…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHold
Price TargetConsensus 12-month target$24.50$315.83$193.81$172.85
# AnalystsCovering analysts8143734
Dividend YieldAnnual dividend ÷ price+0.3%+0.3%+0.3%+2.8%
Dividend StreakConsecutive years of raises02511
Dividend / ShareAnnual DPS$0.05$0.84$0.60$4.17
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.6%0.0%+1.8%
Evenly matched — WST and BDX each lead in 1 of 2 comparable metrics.
Key Takeaway

WST leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GTLS leads in 2 (Total Returns, Risk & Volatility). 1 tied.

Best OverallWest Pharmaceutical Service… (WST)Leads 2 of 6 categories
Loading custom metrics...

STVN vs WST vs GTLS vs BDX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is STVN or WST or GTLS or BDX a better buy right now?

For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.

2% revenue growth year-over-year, versus 2. 5% for Chart Industries, Inc. (GTLS). Becton, Dickinson and Company (BDX) offers the better valuation at 25. 6x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Stevanato Group S. p. A. (STVN) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — STVN or WST or GTLS or BDX?

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 25.

6x versus Chart Industries, Inc. at 628. 6x. On forward P/E, Becton, Dickinson and Company is actually cheaper at 11. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 72x versus West Pharmaceutical Services, Inc. 's 4. 57x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — STVN or WST or GTLS or BDX?

Over the past 5 years, Chart Industries, Inc.

(GTLS) delivered a total return of +40. 6%, compared to -6. 2% for Stevanato Group S. p. A. (STVN). Over 10 years, the gap is even starker: GTLS returned +772. 7% versus STVN's -6. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — STVN or WST or GTLS or BDX?

By beta (market sensitivity over 5 years), Chart Industries, Inc.

(GTLS) is the lower-risk stock at 0. 49β versus Stevanato Group S. p. A. 's 1. 47β — meaning STVN is approximately 198% more volatile than GTLS relative to the S&P 500. On balance sheet safety, West Pharmaceutical Services, Inc. (WST) carries a lower debt/equity ratio of 13% versus 111% for Chart Industries, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — STVN or WST or GTLS or BDX?

By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.

2% versus 2. 5% for Chart Industries, Inc. (GTLS). On earnings-per-share growth, the picture is similar: Stevanato Group S. p. A. grew EPS 14. 0% year-over-year, compared to -92. 0% for Chart Industries, Inc.. Over a 3-year CAGR, GTLS leads at 38. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — STVN or WST or GTLS or BDX?

West Pharmaceutical Services, Inc.

(WST) is the more profitable company, earning 16. 1% net margin versus 1. 0% for Chart Industries, Inc. — meaning it keeps 16. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WST leads at 20. 1% versus 11. 8% for BDX. At the gross margin level — before operating expenses — BDX leads at 45. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is STVN or WST or GTLS or BDX more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 72x versus West Pharmaceutical Services, Inc. 's 4. 57x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 11. 9x forward P/E versus 37. 8x for West Pharmaceutical Services, Inc. — 25. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for STVN: 34. 4% to $24. 50.

08

Which pays a better dividend — STVN or WST or GTLS or BDX?

All stocks in this comparison pay dividends.

Becton, Dickinson and Company (BDX) offers the highest yield at 2. 8%, versus 0. 3% for West Pharmaceutical Services, Inc. (WST).

09

Is STVN or WST or GTLS or BDX better for a retirement portfolio?

For long-horizon retirement investors, Chart Industries, Inc.

(GTLS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 49), +772. 7% 10Y return). Both have compounded well over 10 years (GTLS: +772. 7%, STVN: -6. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between STVN and WST and GTLS and BDX?

These companies operate in different sectors (STVN (Healthcare) and WST (Healthcare) and GTLS (Industrials) and BDX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

BDX pays a dividend while STVN, WST, GTLS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

STVN

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

WST

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Net Margin > 10%
Run This Screen
Stocks Like

GTLS

Quality Business

  • Sector: Industrials
  • Market Cap > $100B
  • Gross Margin > 19%
Run This Screen
Stocks Like

BDX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 1.1%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform STVN and WST and GTLS and BDX on the metrics below

Revenue Growth>
%
(STVN: 3.8% · WST: 21.0%)
Net Margin>
%
(STVN: 11.8% · WST: 16.9%)
P/E Ratio<
x
(STVN: 31.7x · WST: 47.9x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.